Redirecting to https://eisai.mediaroom.com/FDA-Approves-KEYTRUDA-R-pembrolizumab-Plus-LENVIMA-R-lenvatinib-Combination-for-First-Line-Treatment-of-Adult-Patients-With-Advanced-Renal-Cell-Carcinoma-RCC...

Click here if your browser doesn't automatically take you to this page.